GO:0070369 beta-catenin-TCF7L2 complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070369 (beta-catenin-TCF7L2 complex) is a nuclear protein complex containing beta-catenin (CTNNB1) and TCF7L2/TCF4 that binds TCF DNA motifs in WNT target gene promoters.
• The complex is the terminal transcriptional effector of canonical WNT signaling and directly controls target genes such as FERM domain-containing protein 5 (FRMD5) and motile sperm domain containing 1 (MOSPD1).
• Disruption of the beta-catenin-TCF7L2 interaction is a validated therapeutic strategy; matrine blocks complex formation and promotes ferroptosis in triple-negative breast cancer.
• The complex is implicated in multiple malignancies including fibrolamellar hepatocellular carcinoma, diffuse large B cell lymphoma, adult T cell leukemia, colorectal cancer and hepatocellular carcinoma.
• Core experimental approaches include co-immunoprecipitation, ChIP, luciferase reporter assays, knockout and point-mutation cell models, and CRISPR library screening.
• EDITGENE provides knockout, point-mutation, knock-in, overexpression cell models and CRISPR library screening/bioinformatics to dissect beta-catenin-TCF7L2 complex biology.
Description
The beta-catenin-TCF7L2 complex (GO:0070369) is a cellular component defined as a protein complex that contains beta-catenin and TCF7L2 (also known as TCF4), binds to the TCF DNA motif within a promoter element, and regulates WNT target gene transcription. It represents the nuclear endpoint of canonical WNT signaling, converting extracellular WNT cues into changes in gene expression. Because the complex directly controls promoter occupancy and transcriptional output, it is a central node for understanding how WNT signaling drives proliferation, differentiation and survival in normal and diseased tissues. Researchers study GO:0070369 to identify which genes are directly regulated by beta-catenin-TCF7L2, to map its DNA binding sites, and to test whether disrupting the complex changes disease phenotypes. The complex has been linked to cancers of the breast, liver, colon, blood and lymphoid tissues, making it a high-value target for mechanistic and translational studies. This article summarizes the QuickGO definition, the structure and assembly of the complex, its molecular mechanism, key genes, disease associations, and the experimental methods including CRISPR-based models used to study it.
beta-catenin-TCF7L2 complex At A Glance
| GO ID | GO:0070369 |
|---|---|
| GO term | beta-catenin-TCF7L2 complex |
| Ontology | cellular_component |
| Synonym | beta-catenin-TCF4 complex |
| Definition | A protein complex that contains beta-catenin and TCF7L2 (TCF4), binds to the TCF DNA motif within a promoter element, and is involved in the regulation of WNT target gene transcription. |
| Major function | Sequence-specific transcriptional regulation of WNT target genes |
| Key components | beta-catenin (CTNNB1) and TCF7L2/TCF4 |
| DNA element | TCF DNA motif within promoter elements |
| Pathway context | Canonical WNT/beta-catenin signaling |
What Is GO:0070369?
GO:0070369 describes a nuclear protein complex composed of beta-catenin (CTNNB1) and TCF7L2 (TCF4) that binds the TCF DNA motif in promoter elements and regulates transcription of WNT target genes. In practice, it is the transcriptionally active form of beta-catenin: when beta-catenin accumulates and enters the nucleus, it associates with TCF7L2 to form a complex that occupies TCF motifs and activates or represses target genes depending on context.
Why Is beta-catenin-TCF7L2 complex Important in Cell Biology?
GO:0070369 is important because it is the point at which canonical WNT signaling is converted into a specific transcriptional program. The complex binds TCF motifs in promoters and controls genes that influence proliferation, apoptosis resistance, metastasis and differentiation. Pharmacological or genetic disruption of the beta-catenin-TCF7L2 interaction changes disease-relevant phenotypes, as shown by matrine blocking complex formation and promoting ferroptosis in triple-negative breast cancer. Because the complex is recurrently implicated in liver, colon, breast, blood and lymphoid cancers, it is a priority target for mechanistic studies and therapeutic development.
• It is the terminal transcriptional effector of canonical WNT signaling, directly binding TCF motifs in target gene promoters.
• It controls validated WNT target genes such as FRMD5 and MOSPD1, linking the complex to specific downstream biology.
• Blocking beta-catenin-TCF7L2 complex formation with matrine promotes ferroptosis and inhibits metastasis in triple-negative breast cancer.
• The complex contributes to fibrolamellar hepatocellular carcinoma through beta-catenin cancer-enhancing genomic regions.
• FOXP1 potentiates WNT/beta-catenin signaling in diffuse large B cell lymphoma, a context where the complex is active.
• Heat shock protein 90 inhibitors show anti-proliferative activity via the beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
• Visinin-like 1, a target of the WNT/beta-catenin pathway, is involved in apoptosis resistance in colorectal cancer.
• The TCF7L2-binding protein TIP5 activates beta-catenin/TCF signaling in hepatocellular carcinoma.
• The complex provides a defined molecular endpoint for CRISPR screens aimed at WNT pathway dependencies.
• It enables rational design of knockout, point-mutation, knock-in and overexpression models to test causality.
Structure and Composition of beta-catenin-TCF7L2 complex
Core components: beta-catenin and TCF7L2
In simple terms: The complex is built from two main proteins that stick together in the nucleus.
GO:0070369 is defined as a complex containing beta-catenin and TCF7L2 (TCF4). Beta-catenin provides the transactivation surface, while TCF7L2 provides sequence-specific DNA binding to the TCF motif in promoter elements. The two proteins together form the transcriptionally active unit that regulates WNT target genes.
DNA binding to the TCF motif
In simple terms: The complex grabs onto a specific short DNA sequence in gene promoters.
The complex binds the TCF DNA motif within a promoter element, which positions it to regulate transcription of adjacent WNT target genes. This motif-directed binding is what gives the complex its target gene specificity, as illustrated by identification of FRMD5 as a target of the beta-catenin/TCF7L2 complex and by MOSPD1 upregulation through the WNT/beta-catenin pathway.
Assembly and nuclear localization
In simple terms: The complex forms in the nucleus when beta-catenin is available.
Assembly of the beta-catenin-TCF7L2 complex depends on nuclear availability of beta-catenin, which is stabilized when WNT signaling is active. Once formed, the complex occupies TCF motifs and recruits transcriptional machinery to regulate target genes. Disrupting the interaction, for example with matrine, prevents complex formation and alters downstream transcription.
Associated cofactors and modifiers
In simple terms: Other proteins can join or modify the complex to tune its activity.
The complex functions in a broader regulatory environment. The transcription factor 7 like 2-binding protein TIP5 activates beta-catenin/transcription factor signaling in hepatocellular carcinoma, and FOXP1 potentiates WNT/beta-catenin signaling in diffuse large B cell lymphoma. Heat shock protein 90 inhibitors act via the beta-catenin/TCF7L2 pathway in adult T cell leukemia cells, indicating that chaperone machinery influences complex output.
Genomic context of complex action
In simple terms: The complex works at specific regions of the genome that control cancer-related genes.
Beta-catenin cancer-enhancing genomic regions are involved in the development of fibrolamellar hepatocellular carcinoma, showing that the complex operates within defined genomic regulatory landscapes. This context dependence helps explain why the same complex can drive different target gene programs in different tumor types.
Key Genes Involved in GO:0070369 beta-catenin-TCF7L2 complex
The following genes and proteins are directly or functionally linked to the beta-catenin-TCF7L2 complex (GO:0070369) in the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CTNNB1 (beta-catenin) | Core component of the complex; provides transactivation function | Target of matrine, which blocks complex formation in triple-negative breast cancer |
| TCF7L2 (TCF4) | Core component; binds TCF DNA motif in promoters | Defines the complex and its target gene specificity |
| FRMD5 | Identified target of the beta-catenin/TCF7L2 complex | Used to map complex-driven transcription |
| MOSPD1 | Upregulated by the WNT/beta-catenin signaling pathway | Readout of complex activity in colorectal cancer |
| VSNL1 (Visinin-like 1) | Novel target gene of WNT/beta-catenin signaling | Linked to apoptosis resistance in colorectal cancer |
| TIP5 | TCF7L2-binding protein that activates beta-catenin/TCF signaling | Studied in hepatocellular carcinoma |
| FOXP1 | Potentiates WNT/beta-catenin signaling | Studied in diffuse large B cell lymphoma |
| HSP90 | Chaperone influencing beta-catenin/TCF7L2 pathway activity | Targeted by inhibitors in adult T cell leukemia cells |
| WNT ligands (pathway context) | Upstream activators of beta-catenin stabilization | Context for complex assembly |
| APC (pathway context) | Negative regulator of beta-catenin stability | Background for complex-driven transcription |
| AXIN (pathway context) | Scaffold in beta-catenin destruction complex | Background for complex-driven transcription |
| GSK3B (pathway context) | Kinase promoting beta-catenin degradation | Background for complex-driven transcription |
| TCF7L1 (context) | Related TCF family member | Comparative studies of TCF motif binding |
| LEF1 (context) | Related TCF/LEF family member | Comparative studies of TCF motif binding |
| MYC (context) | Classic WNT target gene | Downstream readout of complex activity |
| CCND1 (context) | Classic WNT target gene | Downstream readout of complex activity |
| MMP7 (context) | WNT target gene involved in invasion | Downstream readout of complex activity |
| LGR5 (context) | WNT target gene marking stem cells | Downstream readout of complex activity |
How Is beta-catenin-TCF7L2 complex Regulated?
The beta-catenin-TCF7L2 complex is regulated at multiple levels. Upstream, WNT signaling controls the stability and nuclear availability of beta-catenin, which determines whether the complex can assemble on TCF motifs. Pharmacological disruption of the beta-catenin-TCF7L2 interaction, as shown with matrine, prevents complex formation and changes downstream transcription. Chaperone activity also modulates the pathway, since heat shock protein 90 inhibitors act via the beta-catenin/TCF7L2 pathway in adult T cell leukemia cells. In addition, cofactors such as TIP5 and FOXP1 can enhance beta-catenin/TCF signaling in specific cancer contexts. Together, these layers of regulation determine which target genes are activated and how strongly the complex drives transcription.
beta-catenin-TCF7L2 complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CTNNB1 / TCF7L2 | Triple-negative breast cancer; ferroptosis and metastasis | Knockout or point-mutation breast cancer cell lines with complex-formation assays |
| CTNNB1 | Fibrolamellar hepatocellular carcinoma | Knockout liver cancer cell models with genomic region mapping |
| FOXP1 | Diffuse large B cell lymphoma | Overexpression and knockout lymphoma cell models |
| HSP90 / beta-catenin / TCF7L2 | Adult T cell leukemia | Knockout leukemia cell lines treated with HSP90 inhibitors |
| MOSPD1 / VSNL1 | Colorectal cancer; apoptosis resistance | Knockout and overexpression colorectal cancer cell models |
Breast cancer and metastasis
In triple-negative breast cancer, matrine targets beta-catenin and blocks the formation of the beta-catenin/TCF7L2 complex, promoting ferroptosis and inhibiting metastasis. This demonstrates that the complex is not only a transcriptional node but also a druggable vulnerability in aggressive breast cancer.
Liver cancer
Beta-catenin cancer-enhancing genomic regions are involved in the development of fibrolamellar hepatocellular carcinoma, implicating the complex in liver tumorigenesis. In hepatocellular carcinoma, the TCF7L2-binding protein TIP5 activates beta-catenin/transcription factor signaling, further supporting a role for the complex in liver cancer.
Colorectal cancer
The WNT/beta-catenin pathway upregulates MOSPD1 in colorectal cancer, and Visinin-like 1, a novel target gene of the pathway, is involved in apoptosis resistance in colorectal cancer. These findings link beta-catenin-TCF7L2 complex activity to survival and apoptotic escape in colorectal tumors.
Blood and lymphoid malignancies
FOXP1 potentiates WNT/beta-catenin signaling in diffuse large B cell lymphoma, and heat shock protein 90 inhibitors show anti-proliferative activity via the beta-catenin/TCF7L2 pathway in adult T cell leukemia cells. These studies connect the complex to lymphoid and T cell malignancies.
From beta-catenin-TCF7L2 complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is beta-catenin required for complex formation and target gene activation? | CTNNB1 knockout cell line with TCF motif reporter and target gene readouts |
| Does a specific point mutation in beta-catenin disrupt TCF7L2 binding? | Point-mutation knock-in of CTNNB1 with co-immunoprecipitation and ChIP |
| Can a tagged complex be tracked at target promoters? | Tagged knock-in of TCF7L2 or beta-catenin for ChIP and imaging |
| Does overexpression of a cofactor enhance complex activity? | Overexpression of FOXP1 or TIP5 with WNT reporter assays |
| Which genes depend on the complex for expression? | CRISPR knockout combined with RNA-seq and target gene validation |
| Can pharmacological disruption of the complex change disease phenotypes? | Cell models treated with matrine or HSP90 inhibitors with ferroptosis and proliferation assays |
How to Study the beta-catenin-TCF7L2 complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-immunoprecipitation | Physical interaction between beta-catenin and TCF7L2 | Testing complex formation and disruption by compounds |
| Chromatin immunoprecipitation (ChIP) | Occupancy of TCF motifs in target promoters | Mapping direct target genes such as FRMD5 |
| Luciferase reporter assay | Transcriptional activity driven by TCF motifs | Measuring complex-dependent promoter activity |
| RNA-seq | Global changes in gene expression | Identifying complex-dependent transcriptional programs |
| Western blotting | Protein levels of beta-catenin and TCF7L2 | Confirming knockout, knockdown or overexpression |
| Proliferation assay | Cell growth and viability | Testing effects of complex disruption |
| Apoptosis and ferroptosis assays | Cell death pathways | Linking complex activity to survival and death |
| CRISPR knockout screening | Genes required for complex-driven phenotypes | Identifying dependencies and modifiers |
Co-immunoprecipitation and interaction assays
Co-immunoprecipitation is used to detect physical association between beta-catenin and TCF7L2 and to test whether compounds such as matrine disrupt complex formation. These assays are typically paired with western blotting to quantify complex components in nuclear extracts.
Chromatin immunoprecipitation and promoter analysis
ChIP is used to determine whether the complex occupies TCF motifs in the promoters of target genes such as FRMD5 and MOSPD1. Combining ChIP with reporter assays helps confirm direct transcriptional regulation by the complex.
Transcriptomic profiling of target genes
RNA-seq and targeted expression analysis are used to identify genes whose expression depends on beta-catenin-TCF7L2 activity, including WNT targets such as MOSPD1 and VSNL1. Comparing knockout and control cells reveals the transcriptional program controlled by the complex.
Phenotypic assays for proliferation, apoptosis and ferroptosis
Proliferation, apoptosis and ferroptosis assays are used to connect complex activity to disease-relevant phenotypes, as shown for matrine-treated breast cancer cells and HSP90 inhibitor-treated leukemia cells. These readouts help determine whether disrupting the complex changes cell survival.
How CRISPR Can Be Used to Study GO:0070369 beta-catenin-TCF7L2 complex
Knockout
CRISPR knockout of CTNNB1 or TCF7L2 is used to eliminate the beta-catenin-TCF7L2 complex and test which target genes and phenotypes depend on it. Knockout models are combined with RNA-seq and ChIP to define the complex-dependent transcriptional program.
Point Mutation
Point-mutation knock-in can be used to disrupt specific residues required for beta-catenin-TCF7L2 interaction while preserving other beta-catenin functions. Such models help distinguish complex-dependent transcription from other beta-catenin activities.
Knock-in
Tagged knock-in of beta-catenin or TCF7L2 enables tracking of the complex at promoters and in nuclear compartments. Knock-in reporters of TCF motifs can also be used to monitor complex activity in live cells.
Overexpression
Overexpression of beta-catenin, TCF7L2 or cofactors such as FOXP1 and TIP5 is used to amplify complex activity and test downstream effects on WNT target genes. Overexpression models are useful for validating gain-of-function contributions to cancer phenotypes.
How EDITGENE Supports beta-catenin-TCF7L2 complex Research
Researchers studying beta-catenin-TCF7L2 complex-related genes often need to determine whether a candidate gene is causally involved in complex assembly, target gene regulation or disease phenotypes. EDITGENE provides the CRISPR cell models and screening services needed to move from correlation to causality.
Contact EDITGENE today to design your custom CRISPR model for beta-catenin-TCF7L2 complex research.
Frequently Asked Questions About beta-catenin-TCF7L2 complex
What is the beta-catenin-TCF7L2 complex?
It is a nuclear protein complex (GO:0070369) containing beta-catenin and TCF7L2 (TCF4) that binds the TCF DNA motif in promoters and regulates WNT target gene transcription.
What is GO:0070369?
GO:0070369 is the Gene Ontology identifier for the beta-catenin-TCF7L2 complex, a cellular component involved in WNT target gene transcription.
What genes are involved in the beta-catenin-TCF7L2 complex?
The core genes are CTNNB1 (beta-catenin) and TCF7L2 (TCF4), with associated factors such as FRMD5, MOSPD1, VSNL1, TIP5 and FOXP1.
What does the beta-catenin-TCF7L2 complex do?
It binds TCF motifs in promoters and regulates transcription of WNT target genes, influencing proliferation, apoptosis resistance and metastasis.
How is the beta-catenin-TCF7L2 complex regulated?
It is regulated by WNT-driven beta-catenin stability, by chaperones such as HSP90, and by cofactors such as TIP5 and FOXP1.
Which cancers involve the beta-catenin-TCF7L2 complex?
It has been implicated in triple-negative breast cancer, fibrolamellar hepatocellular carcinoma, colorectal cancer, diffuse large B cell lymphoma and adult T cell leukemia.
Can the beta-catenin-TCF7L2 complex be targeted therapeutically?
Yes; matrine blocks complex formation and promotes ferroptosis in triple-negative breast cancer, and HSP90 inhibitors act via the beta-catenin/TCF7L2 pathway in leukemia cells.
What methods are used to study the beta-catenin-TCF7L2 complex?
Common methods include co-immunoprecipitation, ChIP, luciferase reporter assays, RNA-seq, western blotting and CRISPR knockout models.
How do CRISPR knockouts help study GO:0070369?
Knockout of CTNNB1 or TCF7L2 removes the complex and reveals which target genes and phenotypes depend on it.
What cell models are available for beta-catenin-TCF7L2 research?
Knockout, point-mutation, knock-in, tagged knock-in and overexpression cell models, plus CRISPR library screening, are available from EDITGENE.
Conclusion
GO:0070369 (beta-catenin-TCF7L2 complex) is the nuclear transcriptional effector of canonical WNT signaling, defined by beta-catenin and TCF7L2 binding to TCF motifs in target gene promoters. It controls genes such as FRMD5 and MOSPD1 and is implicated in breast, liver, colorectal, blood and lymphoid cancers. Disrupting the complex is a validated experimental and therapeutic strategy, as shown by matrine and HSP90 inhibitors. Because the complex sits at the intersection of signaling and transcription, precise genetic models are essential. Knockout, point-mutation, knock-in, overexpression and CRISPR screening approaches enable researchers to test causality and identify new targets within the beta-catenin-TCF7L2 network.
References
- 1. Sang Y et al.. 2025. Matrine targets β-catenin and blocks the formation of β-catenin/TCF7L2 complex to promote ferroptosis and inhibit metastasis in triple-negative breast cancer.. Phytomedicine 145:157044 PMID: 40651299
- 2. Zhu C et al.. 2017. Identification of FERM domain-containing protein 5 as a novel target of β-catenin/TCF7L2 complex.. Cancer Sci 108(4):612-619 PMID: 28117551
- 3. Gulati R et al.. 2022. β-catenin cancer-enhancing genomic regions axis is involved in the development of fibrolamellar hepatocellular carcinoma.. Hepatol Commun 6(10):2950-2963 PMID: 36000549
- 4. Walker MP et al.. 2015. FOXP1 potentiates Wnt/β-catenin signaling in diffuse large B cell lymphoma.. Sci Signal 8(362):ra12 PMID: 25650440
- 5. Kurashina R et al.. 2009. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.. Cancer Lett 284(1):62-70 PMID: 19464103
- 6. Horie C et al.. 2022. Motile sperm domain containing 1 is upregulated by the Wnt/β-catenin signaling pathway in colorectal cancer.. Oncol Lett 24(2):282 PMID: 35814826
- 7. Tage H et al.. 2023. Visinin-like 1, a novel target gene of the Wnt/β-catenin signaling pathway, is involved in apoptosis resistance in colorectal cancer.. Cancer Med 12(12):13426-13437 PMID: 37096864
- 8. Li C et al.. 2018. The transcription factor 7 like 2‑binding protein TIP5 activates β‑catenin/transcription factor signaling in hepatocellular carcinoma.. Mol Med Rep 17(6):7645-7651 PMID: 29620186
